HTA202 Health Technology Assessment (HTA) and Reimbursement Decisions for the New Anti-IL-13 Monoclonal Antibody Lebrikizumab for Patients With Moderate to Severe Atopic Dermatitis (AD) in Europe.

Autor: Solé-Feu, L.1 (AUTHOR), Akmaz, B2 (AUTHOR), Joubert, JM3 (AUTHOR), Cressey, M4 (AUTHOR), del Barrio, M5 (AUTHOR)
Zdroj: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS393-S394. 2p.
Databáze: Academic Search Ultimate
Externí odkaz: